Investor's Business Daily on MSN
Eli Lilly stock rebounds as weight-loss drug battle continues
Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...
This biotech has candidates in late-stage clinical development.
The company got some bad news to start 2026.
Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.
Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...
Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic ...
Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...
Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, cash-flow-backed value. Click for my LLY update.
By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...
The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results